Compare Spotify Technology (SPOT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs Twist Bioscience Corp — how do they compare? Spotify Technology trades at $529.44 (market cap $108.22B), while Twist Bioscience Corp trades at $158.85 (market cap $10.08B). The key difference: Spotify Technology is far larger — about 10.7× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spotify Technology for 111 Days and Twist Bioscience Corp for 27 Days on average.
| SPOT | TWST | |
|---|---|---|
Market Cap | $108.22B | $10.08B |
Volume | 1,655,796 | 4,229,037 |
Sector | Media | Health |
52-Week High | $692.04 | $205.00 |
52-Week Low | $412.75 | $25.45 |
Typical Hold Time | 111 Days | 27 Days |
Enterprise Value | $98.23B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish technical signals from moving averages. The company demonstrates robust fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income reaching $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst consensus remains overwhelmingly positive with 62% buy ratings and a $608.18 price target representing 19% upside potential.
The outlook remains favorable with projected 2026 revenue of $18.1B and net income of $3.3B, though risks include competitive pressures in streaming and recent stock volatility. Key catalysts include Q3 2026 earnings release on October 22, 2026, and continued gross margin expansion from 32.8% currently. Institutional sentiment appears constructive given the strong buy-side analyst coverage and improving cash flow trends.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
